接受甲磺酸伊马替尼治疗的慢性髓性白血病患者的色素沉着变化。 - Suppr

Suppr

超能文献

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.

作者信息

Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V

出版信息

Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.

DOI:10.1093/annonc/mdh068

PMID:14760137

Abstract

摘要

相似文献

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.

Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.

A patient of chronic myelogenous leukemia developing painful rash on feet.

J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489.

Imatinib mesylate: a new pill for chronic myelogenous leukemia.

Cancer Pract. 2001 Sep-Oct;9(5):263-5. doi: 10.1046/j.1523-5394.2001.95003.x.

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Br J Haematol. 2003 Mar;120(6):1091-2. doi: 10.1046/j.1365-2141.2003.04208_3.x.

Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.

Leuk Lymphoma. 2007 Jan;48(1):195-6. doi: 10.1080/10428190600923157.

Imatinib mesylate induced immune thrombocytopenia.

Leuk Lymphoma. 2007 Nov;48(11):2261-3. doi: 10.1080/10428190701615934.

Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.

Indian J Dermatol Venereol Leprol. 2006 Jan-Feb;72(1):63-4. doi: 10.4103/0378-6323.19727.

Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.

Leuk Lymphoma. 2006 Jul;47(7):1427-30. doi: 10.1080/10428190600593877.

Imatinib mesylate.

Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.

Imatinib-associated hyperpigmentation, a side effect that should be recognized.

J Eur Acad Dermatol Venereol. 2009 Jan;23(1):82-3. doi: 10.1111/j.1468-3083.2008.02706.x. Epub 2008 Apr 1.

引用本文的文献

Targeted therapies induced depigmentation: a review.

Front Immunol. 2025 Aug 8;16:1625738. doi: 10.3389/fimmu.2025.1625738. eCollection 2025.

Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review.

Cancers (Basel). 2025 Mar 21;17(7):1061. doi: 10.3390/cancers17071061.

Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.

Int J Mol Sci. 2023 May 3;24(9):8188. doi: 10.3390/ijms24098188.

Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

Mol Cell Biochem. 2022 Apr;477(4):1261-1279. doi: 10.1007/s11010-022-04376-6. Epub 2022 Feb 7.

Imatinib Mesylate-Induced Acquired Dermal Melanocytosis and Acquired Bilateral Nevus of Ota-Like Macules.

Ann Dermatol. 2021 Jun;33(3):293-294. doi: 10.5021/ad.2021.33.3.293. Epub 2021 May 4.

J Dent Sci. 2019 Sep;14(3):335-337. doi: 10.1016/j.jds.2019.02.005. Epub 2019 Apr 17.

Imatinib-induced Melasma-like Pigmentation.

Indian J Dermatol. 2019 Mar-Apr;64(2):158-159. doi: 10.4103/ijd.IJD_302_17.

Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.

Clin Oral Investig. 2019 Dec;23(12):4371-4382. doi: 10.1007/s00784-019-02886-0. Epub 2019 Apr 9.

Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors.

JAAD Case Rep. 2019 Jan 30;5(2):170-172. doi: 10.1016/j.jdcr.2018.11.021. eCollection 2019 Feb.

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.

Clin Transl Oncol. 2019 May;21(5):556-571. doi: 10.1007/s12094-018-1953-x. Epub 2018 Oct 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验